| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
35,410,000 |
| Market
Cap: |
693.33(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$13.21 - $21.74 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kiniksa Pharmaceuticals is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with unmet medical need. Co.'s portfolio of assets include: ARCALYST® (rilonacept) is for the treatment of Cryopyrin-Associated Periodic Syndrome; mavrilimumab is targeting granulocyte-macrophage colony stimulating factor receptor alpha; vixarelimab is evaluating vixarelimab for the potential treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404 is a humanized monoclonal antibody that is designed to inhibit the CD40-CD154 interaction.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
128,310 |
194,896 |
224,296 |
274,612 |
| Total Sell Value |
$2,726,499 |
$3,969,036 |
$4,531,208 |
$5,316,305 |
| Total People Sold |
4 |
5 |
5 |
6 |
| Total Sell Transactions |
8 |
12 |
14 |
16 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Patel Sanj K |
CHAIRMAN & CEO |
• • – |
2023-03-16 |
4 |
D |
$11.46 |
$22,106 |
D/D |
(1,929) |
27,036 |
|
- |
|
| Patel Sanj K |
CHAIRMAN & CEO |
• • – |
2023-03-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,569 |
28,965 |
|
- |
|
| Moat Ross |
CHIEF COMMERCIAL OFFICER |
• – – |
2023-01-15 |
4 |
A |
$9.56 |
$17,629 |
D/D |
1,844 |
10,008 |
|
- |
|
| Megna Michael R |
CHIEF ACCOUNTING OFFICER |
• – – |
2023-01-15 |
4 |
A |
$9.56 |
$6,730 |
D/D |
704 |
8,118 |
|
- |
|
| Quart Barry D |
|
– • – |
2022-11-29 |
4 |
S |
$16.15 |
$354,638 |
D/D |
(21,959) |
0 |
|
33% |
|
| Quart Barry D |
|
– • – |
2022-11-29 |
4 |
OE |
$1.59 |
$34,915 |
D/D |
21,959 |
21,959 |
|
- |
|
| Paolini John F. |
CHIEF MEDICAL OFFICER |
• – – |
2022-11-07 |
4 |
AS |
$15.18 |
$430,459 |
D/D |
(28,357) |
36,335 |
|
-26% |
|
| Paolini John F. |
CHIEF MEDICAL OFFICER |
• – – |
2022-11-07 |
4 |
OE |
$1.86 |
$52,744 |
D/D |
28,357 |
64,692 |
|
- |
|
| Megna Michael R |
CHIEF ACCOUNTING OFFICER |
• – – |
2022-10-04 |
4 |
D |
$14.23 |
$740 |
D/D |
(52) |
7,414 |
|
- |
|
| Megna Michael R |
CHIEF ACCOUNTING OFFICER |
• – – |
2022-10-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
175 |
7,466 |
|
- |
|
| Ragosa Mark |
CHIEF FINANCIAL OFFICER |
• – – |
2022-09-02 |
4 |
D |
$11.44 |
$6,258 |
D/D |
(547) |
7,671 |
|
- |
|
| Ragosa Mark |
CHIEF FINANCIAL OFFICER |
• – – |
2022-09-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,861 |
8,218 |
|
- |
|
| Paolini John F. |
CHIEF MEDICAL OFFICER |
• – – |
2022-09-02 |
4 |
D |
$11.44 |
$5,800 |
D/D |
(507) |
36,335 |
|
- |
|
| Paolini John F. |
CHIEF MEDICAL OFFICER |
• – – |
2022-09-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,725 |
36,842 |
|
- |
|
| Megna Michael R |
CHIEF ACCOUNTING OFFICER |
• – – |
2022-09-02 |
4 |
D |
$11.44 |
$2,608 |
D/D |
(228) |
7,291 |
|
- |
|
| Megna Michael R |
CHIEF ACCOUNTING OFFICER |
• – – |
2022-09-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
775 |
7,519 |
|
- |
|
| Moat Ross |
CHIEF COMMERCIAL OFFICER |
• – – |
2022-09-02 |
4 |
D |
$11.44 |
$6,441 |
D/D |
(563) |
8,164 |
|
- |
|
| Moat Ross |
CHIEF COMMERCIAL OFFICER |
• – – |
2022-09-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
995 |
8,727 |
|
- |
|
| Patel Sanj K |
CHAIRMAN & CEO |
• • – |
2022-09-02 |
4 |
D |
$11.44 |
$22,068 |
D/D |
(1,929) |
22,396 |
|
- |
|
| Patel Sanj K |
CHAIRMAN & CEO |
• • – |
2022-09-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,569 |
24,325 |
|
- |
|
| Tessari Eben |
CHIEF OPERATING OFFICER |
• – – |
2022-09-02 |
4 |
D |
$11.44 |
$6,601 |
D/D |
(577) |
114,648 |
|
- |
|
| Tessari Eben |
CHIEF OPERATING OFFICER |
• – – |
2022-09-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,964 |
115,225 |
|
- |
|
| Megna Michael R |
CHIEF ACCOUNTING OFFICER |
• – – |
2022-07-15 |
4 |
A |
$9.56 |
$6,721 |
D/D |
703 |
6,744 |
|
- |
|
| Moat Ross |
CHIEF COMMERCIAL OFFICER |
• – – |
2022-07-15 |
4 |
A |
$9.56 |
$3,442 |
D/D |
360 |
7,732 |
|
- |
|
| Tessari Eben |
CHIEF OPERATING OFFICER |
• – – |
2022-07-15 |
4 |
A |
$9.56 |
$10,019 |
D/D |
1,048 |
113,261 |
|
- |
|
241 Records found
|
|
Page 6 of 10 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.05 (0.26%) 
